CAAA617B12302 PSMAfore

Phase III
Appareil genital masculin, Prostate
Métastatique 1ere ligne

Description de l’essai

Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Novel Androgen Axis Drugs in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer.

Trial sponsor

NOVARTIS

Médecin ICO - Angers

OLIVIER MOREL

Date de début de l'essai

21/06/2021
Lien de l'étude : clinicaltrials.gov